Citi says CSL shares can rise almost 40%

Big returns could be on offer with this beaten down biotherapeutics giant's shares.

| More on:
Man sits smiling at a computer showing graphs

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares are having another tough session.

In afternoon trade, the biotherapeutics company's shares are down 2% to $234.43.

This means its shares are now down approximately 22% over the last six months.

Is it time to load up on CSL shares?

The team at Citi believes there could be some big returns on offer for investors who pick up CSL shares at current levels.

According to a note from this week, the broker has retained its buy rating and $325 price target on its shares.

Based on its current share price, this suggests a potential upside of approximately 39% for investors over the next 12 months.

In addition, the broker is expecting a 1.8% dividend yield in FY 2024, which boosts the potential total return beyond 40%.

What did the broker say?

Citi remains positive on the company following its capital markets and R&D day events.

Following the events, the broker believes the company is on track to achieve the market's expectations in the medium term. As a result, it continues to forecast a mid-teen earnings per share compound annual growth rate all the way through to FY 2028. The broker explains:

CSL held its combined capital markets and R&D day. The information presented was consistent with consensus expectations. CSL remains confident in its ability to generate double-digit EPS growth over the medium-term, in-line with consensus/Citi forecasts of 14%/15% EPS CAGR over FY23-28e.

CSL continues to target Behring GM in-line with pre-pandemic levels (~57-58%) in 3-5 years (consensus FY27/28 of 57%/58%). CSL forecasts Ig market volume growth of 6-8% CAGR over FY23-28 (CSL plans to grow above that) + low-single-digit/CPI price increases despite FcRn competition.

Citi also highlights that management doesn't expect any meaningful impact from Ozempic on its business. This could mean the recent selloff has been a huge overreaction. It adds:

At this stage, CSL doesn't expect GLP-1s to have a significant impact on its Vifor division. There was no change to FY24 guidance. No additional information on CSL112 was provided and Ph3 top-line data will be released in Q1'24. CSL is trading on a PE FY25 of ~23x, a 5x discount to historical average. Maintain Buy, $325 TP.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Two brokers analysing stocks.
Broker Notes

Morgans names 2 ASX shares to buy and 2 to hold

Let's see what the broker is saying about these shares.

Read more »

Hand holding out coal in front of a coal mine.
Broker Notes

Up 379% in 5 years, are Whitehaven Coal shares now a buy, hold or sell?

Here’s what Macquarie is forecasting for Whitehaven Coal shares into 2026.

Read more »

Woman with gold nuggets on her hand.
Broker Notes

Expert tips further upside for this surging ASX 200 gold stock

How much fuel is left in the tank for this gold mining heavyweight?

Read more »

A cute young girl with curly hair sips a glass of milk through a straw with a smile on her face.
Broker Notes

Up 37% this year, why Macquarie expects A2 Milk shares to keep outperforming

Macquarie remains bullish on A2 Milk shares heading into 2026. Let’s see why.

Read more »

ASX shares Business man marking buy on board and underlining it
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

An older female ASX investor holds a gangster-style fist pump pose showing off gold rings with dollar signs on them.
Broker Notes

Why Macquarie forecasts Northern Star shares are set to surge 55%

Macquarie believes Northern Star shares are well-placed to rocket higher.

Read more »

Two miners examine things they have taken out the ground.
Broker Notes

Up 64% this year! What's Macquarie's price target for Lynas Rare Earths shares?

Clouds on the horizon?

Read more »

a group of people in business attire gather around a computer in an office environment with expressions of concern as they try to nut out the answer to a challenge they are facing.
Broker Notes

Leading broker just downgraded the Fortescue share price. Is it time to sell?

Downside ahead for the iron ore titan?

Read more »